Rajula Gaur

Statistics

Publications

Citations

190

H-Index

Active since

2013

Affiliations

Bristol-Myers Squibb (United States)(Current)

Bristol-Myers Squibb (Sweden)

Rajula Gaur is an author at Bristol-Myers Squibb (United States) specializing in medicine, inflammatory disease pharmacotherapy, and covalent inhibition.

Publications per year

2013–2022

Publications

Anti–miR-21 Suppresses Hepatocellular Carcinoma Growth via Broad Transcriptional Network Deregulation

Timothy R. Wagenaar, Sonya Zabludoff, Sung‐Min Ahn et al. · Molecular Cancer Research · 2015 · 75 citations

Medicine, Cancer Biology, Oncology +17

Discovery of CC-99677, a selective targeted covalent MAPKAPK2 (MK2) inhibitor for autoimmune disorders

John Malona, Claudio Chuaqui, Boris M. Seletsky et al. · Translational research · 2022 · 46 citations

Medicine, Medicinal Chemistry, Pharmacology +16

Teriflunomide Attenuates Immunopathological Changes in the Dark Agouti Rat Model of Experimental Autoimmune Encephalomyelitis

Garth E. Ringheim, Lan Lee, Lynn Laws-Ricker et al. · Frontiers in Neurology · 2013 · 42 citations · Full text

Life Sciences, Immunology, Neuroscience +17

CC-99677, a novel, oral, selective covalent MK2 inhibitor, sustainably reduces pro-inflammatory cytokine production

Rajula Gaur, Kofi A. Mensah, Jason M. Stricker et al. · Arthritis Research & Therapy · 2022 · 27 citations · Full text

Medicine, Immunology, Pharmacology +17

1–4 of 4